BACKGROUND Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS A total of 1066 patients were randomly assigned in a 3: 2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.)

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis / Richeldi, Luca; DU BOIS, ROLAND MACLEAN; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, DAVID MATTHEW; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moisés; Taniguchi, Hiroyuki; Brun, Michèle; Le Maulf, Florence; Girard, Mannaïg; Stowasser, Susanne; Schlenker Herceg, Rozsa; Disse, Bernd; Collard, Harold R.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 370:22(2014), pp. 2071-2082. [10.1056/NEJMoa1402584]

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

RICHELDI, Luca;DU BOIS, ROLAND MACLEAN;RAGHU, GANESH;HANSELL, DAVID MATTHEW;
2014

Abstract

BACKGROUND Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS A total of 1066 patients were randomly assigned in a 3: 2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.)
2014
370
22
2071
2082
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis / Richeldi, Luca; DU BOIS, ROLAND MACLEAN; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, DAVID MATTHEW; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moisés; Taniguchi, Hiroyuki; Brun, Michèle; Le Maulf, Florence; Girard, Mannaïg; Stowasser, Susanne; Schlenker Herceg, Rozsa; Disse, Bernd; Collard, Harold R.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 370:22(2014), pp. 2071-2082. [10.1056/NEJMoa1402584]
Richeldi, Luca; DU BOIS, ROLAND MACLEAN; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell,...espandi
File in questo prodotto:
File Dimensione Formato  
INPULSIS-NEJM-2014-Nintedanib-IPF.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 565.44 kB
Formato Adobe PDF
565.44 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1091060
Citazioni
  • ???jsp.display-item.citation.pmc??? 1632
  • Scopus 3263
  • ???jsp.display-item.citation.isi??? 3007
social impact